Zacks: Brokerages Expect Ampio Pharmaceuticals, Inc. (NYSE:AMPE) to Announce -$0.02 EPS

Wall Street brokerages expect Ampio Pharmaceuticals, Inc. (NYSE:AMPEGet Rating) to report earnings of ($0.02) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals also reported earnings of ($0.02) per share in the same quarter last year. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Ampio Pharmaceuticals will report full year earnings of ($0.08) per share for the current fiscal year. For the next year, analysts forecast that the company will post earnings of ($0.08) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Ampio Pharmaceuticals.

Ampio Pharmaceuticals (NYSE:AMPEGet Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02).

Separately, assumed coverage on shares of Ampio Pharmaceuticals in a research note on Wednesday, May 18th. They set a “sell” rating for the company.

NYSE AMPE traded down $0.01 during trading hours on Wednesday, hitting $0.16. 54,616 shares of the company’s stock traded hands, compared to its average volume of 2,429,256. Ampio Pharmaceuticals has a 52-week low of $0.16 and a 52-week high of $1.98. The company has a market cap of $36.78 million, a P/E ratio of -1.50 and a beta of 1.84. The company’s 50-day moving average is $0.33.

Ampio Pharmaceuticals Company Profile (Get Rating)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

See Also

Get a free copy of the Zacks research report on Ampio Pharmaceuticals (AMPE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.